Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-9815 PET/CT Imaging in Prostate Cancer
NCT06062355Phase 1Not yet recruiting
- Sponsor
- Hengrui
- Start
- Oct 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of gallium Ga 68 labeled PSMA-targeting radiodiagnostic agent HRS-9815 in prostate cancer (PCa), sponsored by Hengrui. Primary endpoint: Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 30 days. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
gallium Ga 68 labeled PSMA-targeting radiodiagnostic agent HRS-9815
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06062355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06062355.